The organization released principles related to workforce development, diversity, and inclusion that it believes are key to the biotechnology industry.
On June 19, 2017, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. BIO also established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry. The committee will be chaired by Helen Torley, president and CEO of Halozyme, who is succeeding Julie Gerberding, executive vice-president and chief patient officer at Merck, who led the committee as it developed BIO’s WDDI principles over the last year.
The principles on WDDI adopted today by BIO’s Board of Directors state that BIO considers diversity to be essential to the success of the biotechnology industry. In a press release, the organization named the following principles as key to this plan.
The organization will also discuss workforce development, diversity, and inclusion during the 2017 BIO International Convention in San Diego, CA from June 19–22, 2017.
Source: BIO
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.